An interventional study of Tetrahydrocannabinol (10 mg) and Tetrahydrocannabinol (25 mg) in Cannabis Intoxication and Drug Effects, sponsored by Sobereye Inc.. Completed at 1 site in Canada. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Sobereye Inc. · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this open label study is to evaluate the efficacy of smart phone-based test (SOBEREYE OPTOVERA) on measuring pupillary light reflex (PLR) alterations following cannabis use healthy in adults. The main question it aims to answer is:
Can SOBEREYE OPTOVERA detect PLR alterations following cannabis consumption in healthy adults, in comparison to a pupillometer?
Participants will be given two 5 mg capsules to be ingested for the 10 mg THC dose or five 5 mg capsules to be ingested for the 25 mg THC. Participants will be asked to complete PLR tests throughout the study day.
This is the only study on the registry with Sobereye Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females not of , defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been for at least 1 year prior to screening Or,
Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule.
Drug: Tetrahydrocannabinol (10 mg) · Diagnostic Test: Pupillary Light Reflex (PLR) Test · Diagnostic Test: Pupillometer
25 mg of THC provided as a softgel capsule.
Drug: Tetrahydrocannabinol (25 mg) · Diagnostic Test: Pupillary Light Reflex (PLR) Test · Diagnostic Test: Pupillometer
10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule
25 mg of THC provided as a softgel capsule.
SOBEREYE OPTOVERA is a portable, non-invasive test that measures the Pupillary Light Reflex (PLR)
NeuroLight is an automated pupillometer that generates a flash of light and measures the photomotor reflex very accurately.
The difference in change in Pupillary Light Reflex (PLR) measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=5 min.
Time frame: T=0 to T=5 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=30 min.
Time frame: T=0 to T=30 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=60 min.
Time frame: T=0 to T=60 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=120 min.
Time frame: T=0 to T=120 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=180 min.
Time frame: T=0 to T=180 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=240 min.
Time frame: T=0 to T=240 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=300 min.
Time frame: T=0 to T=300 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=360 min.
Time frame: T=0 to T=360 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=420 min.
Time frame: T=0 to T=420 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=480 min.
Time frame: T=0 to T=480 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=5 min.
Time frame: T=0 to T=5 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=30 min.
Time frame: T=0 to T=30 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=60 min.
Time frame: T=0 to T=60 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=120 min.
Time frame: T=0 to T=120 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=180 min.
Time frame: T=0 to T=180 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=240 min.
Time frame: T=0 to T=240 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=300 min.
Time frame: T=0 to T=300 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=360 min.
Time frame: T=0 to T=360 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil reflexes (absolute contraction and latency) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=480 min.
Time frame: T=0 to T=480 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer in pupil size from time (T)=0 minutes (min) at T=5 min.
Time frame: T=0 to T=5 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=30 min.
Time frame: T=0 to T=30 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=60 min.
Time frame: T=0 to T=60 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=120 min.
Time frame: T=0 to T=120 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=180 min.
Time frame: T=0 to T=180 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=240 min.
Time frame: T=0 to T=240 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=300 min.
Time frame: T=0 to T=300 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=360 min.
Time frame: T=0 to T=360 minutes
The difference in change in PLR measures between a smart phone-based test and NeuroLight pupillometer
The difference in change in pupil activity as measured by pupillary unrest in ambient light (hippus) between a smart phone-based test and NeuroLight pupillometer from time (T)=0 minutes (min) at T=480 min.
Time frame: T=0 to T=480 minutes
The difference in change in reaction time
The difference in change in reaction time as assessed by Dynavision from T= 0 at T=60 minutes
Time frame: T= 0 at T=60 minutes
The difference in change in reaction time
The difference in change in reaction time as assessed by Dynavision from T= 0 at T=120 min
Time frame: T= 0 at T=120 minutes
The difference in change in reaction time
The difference in change in reaction time as assessed by Dynavision from T= 0 at T=180 minutes
Time frame: T= 0 at T=180 minutes
The difference in change in reaction time
The difference in change in reaction time as assessed by Dynavision from T= 0 at T=240 minutes
Time frame: T= 0 at T=240 minutes
The difference in change in reaction time
The difference in change in reaction time as assessed by Dynavision from T= 0 at T=300 minutes
Time frame: T= 0 at T=300 minutes
The difference in change in reaction time
The difference in change in reaction time as assessed by Dynavision from T= 0 at T=360 min
Time frame: T= 0 at T=360 minutes
The difference in change in reaction time
The difference in change in reaction time as assessed by Dynavision from T= 0 at T=420 min
Time frame: T= 0 at T=420 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T= 5 min, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T= 5 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=30 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=30 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=60 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=60 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=90 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=90 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=120 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=120 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=180 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=180 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=240 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=240 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=300 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=300 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=360 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=360 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=420 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=420 minutes
The difference in change in subjective drug effects
The difference in change in subjective drug effects as assessed by the modified Drug Effects Questionnaire (DEQ) from T=0 at T=480 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 at T=480 minutes
Clinically relevant post-emergent adverse events
Clinically relevant post-emergent adverse events at T=0 to T=480 minutes. Including via the modified Drug Effects Questionnaire (DEQ) from T=0 at T=480 minutes, on a scale of 1 to 10. Higher score indicates higher subjective drug effect.
Time frame: T=0 to T=480 minutes
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Aug 2025, 2 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol